The historical data trend for CytoMed Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CytoMed Therapeutics's EV-to-EBIT
For the Biotechnology subindustry, CytoMed Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's EV-to-EBIT falls into.
CytoMed Therapeutics's current Enterprise Value is $22.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CytoMed Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CytoMed Therapeutics's Enterprise Value for the quarter that ended in Dec. 2024 was $35.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CytoMed Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of CytoMed Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GDTC has been successfully added to your 